Your browser doesn't support javascript.
loading
[IgG4-related ophthalmic disease: three-case report].
Cao, S S; Zhou, H F; Wei, S H.
Afiliación
  • Cao SS; Department of Ophthalmology, the First Medical Center of Chinese PLA General Hospital, Beijing 100853, China.
  • Zhou HF; Department of Ophthalmology, the First Medical Center of Chinese PLA General Hospital, Beijing 100853, China.
  • Wei SH; Department of Ophthalmology, the First Medical Center of Chinese PLA General Hospital, Beijing 100853, China.
Zhonghua Yan Ke Za Zhi ; 57(5): 375-378, 2021 May 11.
Article en Zh | MEDLINE | ID: mdl-33915642
ABSTRACT
The first patient complained visual loss of left eye for 1 week. The second patient complained visual loss of right eye for 2 months with conjunctival edema for more than 10 days. The third patient complained redness and swelling of both eyes for 1 year, poor appetite and fatigue for 4 months. All three patients were male with binocular involvement. Enlargement of lacrimal glands in both eyes with bulbar conjunctival edema were observed in 2 patients and binocular eyelid swelling in 1 patient, all 3 patients were associated with external orbital tissue involvement, which were diagnosed as IgG4-related ophthalmic diseases. After treatment with glucocorticoid, the symptoms of the patients were improved, and the patients were followed up for 58, 54, and 60 months, respectively. Among the 3 patients, 2 had recurrence for once, and 1 had recurrence 3 for times. (Chin J Ophthalmol, 2021, 57 375-378).
Asunto(s)

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Oftalmopatías / Enfermedad Relacionada con Inmunoglobulina G4 / Aparato Lagrimal Límite: Female / Humans / Male Idioma: Zh Revista: Zhonghua Yan Ke Za Zhi Año: 2021 Tipo del documento: Article País de afiliación: China

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Oftalmopatías / Enfermedad Relacionada con Inmunoglobulina G4 / Aparato Lagrimal Límite: Female / Humans / Male Idioma: Zh Revista: Zhonghua Yan Ke Za Zhi Año: 2021 Tipo del documento: Article País de afiliación: China